Loading page…
The government’s decision on a £330 million health-data contract now sits alongside a rise in research opt-outs and unresolved questions over the platform’s claimed results.
Listen to this story
The UK’s NHS data-platform dispute now includes a participation risk: 60,000 additional people opted out of research and planning data use between mid-May and mid-July. Health Innovation Minister James Frith said mistrust of Palantir could weaken future data sharing, while ministers consider terminating the company’s £330 million, seven-year NHS federated data platform contract.
The 60,000 opt-outs do not block use of NHS records for an individual’s direct care.
Ministers are considering a break clause in Palantir’s £330 million, seven-year agreement.
NHS trusts can choose alternatives, so local adoption may diverge from the national contract decision.
An additional 60,000 people withdrew consent for their NHS information to be used in research and planning from mid-May to mid-July, as Health Innovation Minister James Frith warned that mistrust of Palantir could make patients less willing to share data.
The opt-outs use a national mechanism that stops records being used for research and planning, while leaving their use for an individual’s direct care intact. Frith described the increase as modest, but said it would be monitored. His warning puts confidence in the data system alongside the government’s pending contract decision.
The UK government is deciding whether to terminate Palantir’s £330 million, seven-year agreement to operate the NHS federated data platform, a system intended to improve efficiency and patient outcomes. Doctors and patients’ groups want ministers to use a break clause in that agreement.
Frith also said NHS trusts are not required to use the platform and may prefer an alternative. That leaves local adoption separate from the national contract: the agreement could remain in place even as individual trusts choose other systems.
Palantir says trusts using its technology recorded 110,000 additional operations, a 15% reduction in discharge delays for long-stay patients, and a 6.8% improvement in 28-day cancer-result notification rates. Those are company-supplied figures offered as evidence that the platform is improving care.
NHS England has reported similar figures but said it could not draw conclusions about cause and effect. The UK government’s statistics watchdog is investigating the data, leaving the claimed benefits under scrutiny as ministers weigh the contract’s future.
The choice is no longer only whether Palantir’s platform delivers operational gains. Frith’s concern is that mistrust of the supplier could reduce participation in the research and planning data on which the NHS relies, even if the platform stays available.
Loading discussion...
Join the conversation
Explain what should matter most in that decision.
Be the first to share a perspective or an experience.
Reader comments
Newest comments first. Replies stay oldest first.